AG
VRTX icon

Ascent Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Ascent Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Sell
3,701
-709
-16% -$314K 0.06% 278
2026
Q1 		$1.97M Sell
4,410
-1,085
-20% -$506K 0.07% 254
2025
Q4 		$2.49M Sell
5,495
-1,124
-17% -$484K 0.09% 215
2025
Q3 		$2.59M Sell
6,619
-2,033
-23% -$850K 0.09% 203
2025
Q2 		$3.85M Sell
8,652
-790
-8% -$364K 0.15% 139
2025
Q1 		$4.58M Sell
9,442
-1,345
-12% -$627K 0.2% 111
2024
Q4 		$4.34M Sell
10,787
-9
-0.1% -$4.17K 0.33% 78
2024
Q3 		$5.02M Buy
10,796
+1,763
+20% +$847K 0.38% 56
2024
Q2 		$4.23M Buy
9,033
+416
+5% +$181K 0.34% 65
2024
Q1 		$3.6M Sell
8,617
-4,759
-36% -$2.01M 0.32% 76
2023
Q4 		$5.6M Buy
13,376
+1,612
+14% +$595K 0.53% 38
2023
Q3 		$4.34M Buy
11,764
+38
+0.3% +$13.3K 0.48% 44
2023
Q2 		$4.04M Buy
11,726
+3,239
+38% +$1.09M 0.45% 46
2023
Q1 		$2.67M Buy
8,487
+3,522
+71% +$1.06M 0.28% 87
2022
Q4 		$1.43M Buy
4,965
+671
+16% +$205K 0.17% 174
2022
Q3 		$1.34M Buy
4,294
+3,186
+288% +$917K 0.16% 171
2022
Q2 		$311K Buy
+1,108
New +$297K 0.04% 382

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ascent Group's VRTX Position: Q2 2026 in Review

Ascent Group reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2026, selling an estimated $314K and leaving 3,701 shares worth $1.84M. The position accounts for 0.06% of the portfolio, ranked #278.

Ascent Group first reported a position in VRTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $5.6M in Q4 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ascent Group held 3,701 shares of Vertex Pharmaceuticals worth $1.84M as of Q2 2026.
  • Ascent Group sold 709 Vertex Pharmaceuticals shares in Q2 2026, an estimated $314K.
  • Vertex Pharmaceuticals made up 0.06% of Ascent Group's portfolio in Q2 2026, its #278 holding.
  • Ascent Group first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Ascent Group's Vertex Pharmaceuticals position peaked at $5.6M in Q4 2023.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.